Osteogenic Growth Peptide

OGP is a 14-residue peptide identical to the C-terminal region of histone H4, found circulating at high nanomolar concentrations bound to OGP binding protein, which acts as a reservoir. The biologically active species is the C-terminal pentapeptide OGP(10-14), released proteolytically from the parent. It increases osteoblast number and alkaline phosphatase activity, promotes mineralised matrix formation, and separately stimulates haematopoiesis - it was originally identified through post-injury marrow regeneration. The signalling runs through a pertussis-toxin-sensitive Gi-coupled receptor into MAPK/ERK and Src. All of this is characterised in rodents and cell culture; there is no human clinical programme.

Targets: Gi-coupled OGP receptor, MAPK / ERK signalling, Src kinase, Osteoblast proliferation and mineralisation, Haematopoietic progenitors

• · Be clear that no human dose has ever been established for OGP. This range comes from vendor suggestion and community practice, not from a trial, and there is no way to know whether it is under-dosed, over-dosed or simply inert.

Work out your exact syringe units →

• commonInjection-site irritation
• commonUnknown profile— There is no human safety data for this peptide at all, so any adverse-effect list is speculation.

• Active malignancy, particularly bone metastases or haematological cancer - a peptide that stimulates both osteoblasts and haematopoietic progenitors is the wrong thing to add.
• Any situation where a mineralising signal could accelerate heterotopic ossification.

• synergybpc-157 — Commonly stacked for fracture and bone stress injury, on theoretical grounds only.

• · Serial imaging is the only meaningful way to assess bone healing; symptoms alone are not reliable.
• · No established bloodwork.

Not approved for human use anywhere; sold as a research chemical.

• Bab & Chorev, osteogenic growth peptide - from concept to drug design (review) (review)
• Greenberg et al., mitogenic action of osteogenic growth peptide OGP(10-14) via MAP kinase and Src (preclinical)

OGP was found because bone marrow regenerates after injury and something in the regenerating marrow was driving osteogenesis. It turned out to be a peptide identical to the tail of histone H4, which is an unusual origin - a nuclear structural protein fragment acting as an extracellular signal. The pharmacology has a two-stage structure that is genuinely important. The 14-mer circulates at high nanomolar concentrations bound to a carrier protein and is essentially a prodrug reservoir. The active molecule is the pentapeptide OGP(10-14), cleaved from the C-terminus. Anything you inject as the 14-mer has to be processed before it does anything. Signalling runs through a pertussis-toxin-sensitive Gi-coupled receptor that has never been cloned or identified - which is a real gap, because it means nobody can screen for selectivity or measure affinity. Downstream it activates MAPK/ERK and Src, which drives osteoblast proliferation, alkaline phosphatase activity and mineralised matrix formation. The second effect is haematopoietic. OGP and OGP(10-14) increase marrow cellularity and enhance engraftment after bone marrow transplant in animal models. That is a real finding and it is also the specific reason haematological malignancy is a contraindication - you would be feeding a proliferative signal to exactly the compartment involved. And then the honest part: there is no human clinical programme. Not a failed one, not a discontinued one - none. There is no human dose, no human pharmacokinetic data and no human safety data. The 100-500 mcg daily range in circulation comes from vendor suggestion. Given that the active species is a metabolite and the receptor is unidentified, there is no principled way to convert rodent findings into a human dose, and no way to know whether the community protocol is under-dosed, over-dosed or simply inert.

The main failure is that you cannot tell whether anything is happening. Bone healing is judged on serial imaging over weeks, most fractures heal anyway, and there is no biomarker anyone has validated for OGP. That combination makes it almost impossible to attribute an outcome to the peptide, which is why the anecdotal literature on OGP is thin even by the standards of this class. The second is the dose. The 100-500 mcg daily band has no basis in any species at human-equivalent exposure. Given that the injected 14-mer must be cleaved to the pentapeptide before it does anything, and the receptor has never been identified, there is no principled way to reason about whether that band is anywhere near right. The third is masking a non-union. Persistent pain at a fracture site that is not healing needs imaging and often surgical fixation. Adding a peptide and waiting is how a six-week problem becomes a plate and screws. The fourth is the malignancy contraindication, which is more specific here than the generic version. A compound that stimulates both osteoblasts and haematopoietic progenitors is a poor addition for anyone with bone metastases, myeloma or a haematological cancer. And the fifth is opportunity cost. Vitamin D, calcium, protein, load management and smoking cessation all have documented effects on fracture healing. OGP has none in humans.

• Unidentified Gi-coupled OGP receptor — Pertussis-toxin-sensitive, indicating Gi coupling. The receptor has never been cloned and no binding constant exists.

  Upstream of the MAPK and Src signalling that produces the osteogenic effect. The fact that it is unidentified is the central unknown in this compound's pharmacology.

• MAPK / ERK signalling — Downstream, not a binding target

  Mitogenic signal driving osteoblast proliferation.

• Src kinase — Downstream

  Contributes to the proliferative and differentiation response in osteoblastic lineage cells.

• Osteoblast differentiation and mineralisation — Cellular endpoint

  Increased alkaline phosphatase activity and mineralised matrix formation in culture and in rodent fracture models.

• Haematopoietic progenitors — Cellular endpoint

  Increased marrow cellularity and improved engraftment after transplant in animal models. Also the basis of the haematological malignancy contraindication.

• No human trial of osteogenic growth peptide has ever been conducted None

  There is no clinical programme, no phase 1 safety study and no established human dose. The entire evidence base is rodent fracture and marrow models plus cell culture. This is the thinnest evidence base of any injectable compound in this class.

There is no human onset data to quote, and inventing one would be dishonest. In rodent models, bone healing endpoints take three to six weeks. In human terms, if you are running this around a fracture: cortical bridging on imaging is a six-to-twelve-week question depending on the bone, and it would happen without the peptide. Any assessment of OGP has to be against a serial imaging baseline, which almost nobody does. Bone turnover markers would move faster than imaging if the compound is doing anything - P1NP responds to changes in osteoblast activity within weeks - which is why they are in the bloodwork list despite never having been studied on this compound.

OGP is stacked with BPC-157 around fractures and bone stress injuries on purely theoretical grounds - angiogenesis into the callus from one, osteoblast stimulation from the other. There is no data on the combination and no data on OGP alone in humans, so this is two unknowns being multiplied. The things that genuinely matter alongside it are unglamorous: adequate vitamin D and calcium, enough total protein, mechanical loading appropriate to the stage of healing, and stopping smoking if applicable, which has a larger documented effect on fracture healing than anything in this encyclopedia. With collagen peptides there is a substrate argument for bone matrix, and collagen peptides at least have human trials, albeit not for fracture healing specifically. Do not stack it with anything while a heterotopic ossification risk exists - after major joint surgery, spinal cord injury or significant burns. A mineralising signal in that context is aimed at the wrong tissue.

Against teriparatide or abaloparatide for bone: those are approved anabolic drugs with large randomised fracture-reduction trials. OGP has rodent data. If bone density or non-union is a genuine clinical problem, the approved options exist and this is not a substitute. Against BPC-157 for a bone stress injury: BPC-157 at least has a large rodent literature across many tissue types and a widely used dose band. OGP has a narrower rodent literature and no dose rationale at all. Against load management and vitamin D repletion for a stress fracture: the boring options have the evidence. This is not a rhetorical point - relative energy deficiency and vitamin D deficiency are the two most common reversible causes of recurrent bone stress injury in athletes, and neither responds to a peptide. Against collagen peptides: those have human randomised trials for joint and skin endpoints, and a mechanistic case for bone matrix substrate. Cheaper, safer and better supported, though not specifically trialled for fracture healing.

$30–$90/month. Order-of-magnitude estimate for research-chemical vials at 100-500 mcg daily. Note that most vendors sell the 14-mer while some sell OGP(10-14); they are different molecules at different molar doses. Not price-checked in the preparation of this entry.

• ?No human pharmacokinetics, no human dose, no human safety data and no human trial of any phase. This is the thinnest evidence base of any injectable compound in this class.
• ?The OGP receptor has never been cloned or identified beyond being pertussis-toxin-sensitive and Gi-coupled, so no affinity or selectivity data can exist.
• ?The molecular weight of the 14-mer is not stated in the Core record and was not independently confirmed in this session.
• ?Whether injected 14-mer OGP is processed to the active OGP(10-14) pentapeptide efficiently in humans is unknown.
• ?Vendors sell both the 14-mer and OGP(10-14) under the same name, at very different molecular weights, so a microgram dose means different things depending on the product.
• ?The 100-500 mcg daily community band has no basis in any published study.
• ?Cost figures are estimates and were not price-verified in this session.

• Osteogenic growth peptide: from concept to drug design Bab I, Chorev M, Biopolymers, 2002 · PMID 12228919

  The definitive review from the group that discovered it. Source for the OGP(10-14) active-fragment structure, the histone H4 identity and the haematopoietic effects.